Recombinant mouse TFPI proteins (mouse rTFPI; R&D Systems) were injected intravenously (i.v.) into mice at a dose of 50 μg/kg for 5 days. mouse rTFPI and human rTFPI (R&D Systems) were added to the cell culture medium at a concentration of 200 ng/ml. Anti-TFPI monoclonal antibodies (Concizumab, Creative Biolabs, Shirley, New York, NY, USA) were injected i.v. into mice at a dose of 5 mg/kg. Anti-TF monoclonal antibodies were generated and injected i.v. into mice at a dose of 20 mg/kg. SCH772984, a ERK1/2 inhibitor, was injected intraperitoneally (i.p.) into mice at a dose of 10 mg/kg for 7 days. AS1842856, a FOXO1 inhibitor, was injected i.p. into mice at a dose of 10 mg/kg for 7 days. JNK-IN-8, a JNK inhibitor, was injected i.p. into mice at a dose of 10 mg/kg for 7 days. In BrdU incorporation assays, 1 mg of BrdU was administered to mice by i.p. injection, Ter119+CD71+ cells were collected and processed according to the manufacturer’s instructions in the BrdU Kit (BD Biosciences, San Jose, CA, USA).
Ma J.K., Su L.D., Feng L.L., Li J.L., Pan L., Danzeng Q., Li Y., Shang T., Zhan X.L., Chen S.Y., Ying S., Hu J.R., Chen X.Q., Zhang Q., Liang T, & Lu X.J. (2024). TFPI from erythroblasts drives heme production in central macrophages promoting erythropoiesis in polycythemia. Nature Communications, 15, 3976.
+ Open protocol